Clinical Trial and Regulatory Approval Failures: BioMarin's future growth heavily depends on the successful completion of clinical trials and obtaining regulatory approvals for its pipeline products, especially for new indications or next-generation therapies.

Intense Market Competition: The rare disease pharmaceutical market is highly competitive. Existing or new competitors could develop more effective, safer, or more affordable treatments, eroding BioMarin's market share and profitability for its key products like Voxzogo, Vimizim, and Naglazyme.

Intellectual Property Infringement and Expiry: BioMarin's success relies on its ability to obtain and defend patent protection for its products. Loss of patent exclusivity or challenges to its intellectual property rights could lead to generic or biosimilar competition, significantly impacting revenues.